One shot may shield HIV-Positive women from HPV
NCT ID NCT06436274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single dose of the HPV vaccine (Gardasil 9) can prevent persistent HPV infection in women living with HIV who have already been vaccinated. About 778 women will receive either the HPV vaccine or a meningitis vaccine (placebo) and be monitored for safety and infection. The goal is to see if one dose is enough to protect this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV vaccine (Gardasil 9)
What this could lead to
If successful, a single HPV vaccine dose could protect women with HIV from persistent HPV infection, reducing cancer risk.
What could go wrong
This is a Phase 4 study, but results may not apply to all populations. The single-dose approach may be less effective than the standard series, and safety in this group is still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Botswana Harvard Health Partnership
Gaborone, 0000, Botswana
-
Ministry of Health and Center for Family Health Research
Kigali, Kigali, +250, Rwanda
-
Wits RHI, University of the Witwatersrand
Johannesburg, Gauteng, 2001, South Africa